Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Beta-1a (REBIF 44mg 3 Times / Week) Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis

NCT02937285 is registered in ClinicalTrials.gov with Rennes University Hospital as lead sponsor.

NCT NCT02937285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02937285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Beta-1a (REBIF 44mg 3 Times / Week) Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
Lead sponsor
Rennes University Hospital
Phase
Phase 3
Overall status
Completed
Start date
December 6, 2010
Completion date
May 28, 2020
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis